s

Senzime’s Interim report January – September 2017

“The third quarter has been characterized by continued high activity with a number of important events before market launch of our ISO-certified monitoring systems - TetraGraph, OnZurf and CliniSenz. We previously assessed that we would have CE approvals before this report, but we can only state - CE processes are challenging with significantly higher requirements for medical device approvals in our markets. Our assessment is still that we will receive approvals shortly. We will report on a regular basis. However, we are pleased that despite the long CE process, we have had an active third quarter. We are making great progress; the CE processes are challenging, but the assessment that CE approvals are imminent will remain and as soon as they are received, we will announce this, after which a broad market launch will begin.” Says Lena Söderström, CEO of Senzime.

Financial information third quarter 2017

  • Net sales amounts to KSEK 0 (900)
  • Income after financial items amounts to KSEK -2,455 (-1,964).
  • Earnings per share before dilution amounts to SEK -0.06 (-0.06).

Financial information January - September 2017

  • Net sales amounts to KSEK 174 (1,443)
  • Income after financial items amounts to KSEK -9,356 (-5,840).
  • Earnings per share before dilution amounts to SEK -0.24 (-0.24).

For further information, please contact:

Jessica Roxhed, CFO

Tel: +46 703-94 94 98, e-mail: jessica.roxhed@senzime.com 

TO THE EDITORS  

About Senzime  

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com 

This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on November 28th 2017.